ESTIMATED
08/30/2023
08/30/2023
(AS OF MARCH 31)
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 0 | -$0.36 | -$0.36 | -$0.36 |
Q2 2024 | 0 | -$0.49 | -$0.49 | -$0.49 |
Q3 2024 | 0 | -$0.50 | -$0.50 | -$0.50 |
Q4 2024 | 0 | -$0.48 | -$0.48 | -$0.48 |
Q1 2025 | 0 | -$0.35 | -$0.35 | -$0.35 |
Q2 2025 | 0 | -$0.35 | -$0.35 | -$0.35 |
Q3 2025 | 0 | -$0.33 | -$0.33 | -$0.33 |
Q4 2025 | 0 | -$0.07 | -$0.07 | -$0.07 |
Q1 2026 | 0 | -$0.24 | -$0.24 | -$0.24 |
Q2 2026 | 0 | -$0.08 | -$0.08 | -$0.08 |
Q3 2026 | 0 | -$0.18 | -$0.18 | -$0.18 |
Q4 2026 | 0 | -$0.37 | -$0.37 | -$0.37 |
Q1 2027 | 0 | -$0.39 | -$0.39 | -$0.39 |
Q2 2027 | 0 | -$0.26 | -$0.26 | -$0.26 |
Q3 2027 | 0 | -$0.19 | -$0.19 | -$0.19 |
Q4 2027 | 0 | -$0.31 | -$0.31 | -$0.31 |
Q1 2028 | 0 | -$0.27 | -$0.27 | -$0.27 |
Q2 2028 | 0 | -$0.31 | -$0.31 | -$0.31 |
Q3 2028 | 0 | -$0.28 | -$0.28 | -$0.28 |
Q4 2028 | 0 | -$0.43 | -$0.43 | -$0.43 |
Q1 2029 | 0 | -$0.36 | -$0.36 | -$0.36 |
Q2 2029 | 0 | -$0.36 | -$0.36 | -$0.36 |
Q3 2029 | 0 | -$0.24 | -$0.24 | -$0.24 |
Q4 2029 | 0 | -$0.21 | -$0.21 | -$0.21 |
Q1 2030 | 0 | -$0.21 | -$0.21 | -$0.21 |
Mesoblast Limited last posted its earnings results on Wednesday, August 30th, 2023. The company reported $-0.28 earnings per share for the quarter, topping analysts' consensus estimates of $-0.32 by $0.04. The company had revenue of 1.69 M for the quarter and had revenue of 7.50 M for the year. Mesoblast Limited has generated $-1 earnings per share over the last year ($-1.05 diluted earnings per share) and currently has a price-to-earnings ratio of -90.21. Mesoblast Limited has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 28th, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 02/29/2024 | Q2 2024 | -$0.02 | $6.84 M | $1.69 M | 08/31/2023 | Q1 2024 | -$0.02 | $5.60 M | $1.69 M | 08/30/2023 | Q4 2023 | -$0.28 | $2.38 M | $2.14 M | 05/25/2023 | Q3 2023 | -$0.24 | $2.14 M | $1.94 M | 02/27/2023 | Q2 2023 | -$0.32 | $2.10 M | $1.98 M | 08/31/2022 | Q1 2023 | -$0.12 | $3.47 M | $1.44 M | 08/31/2022 | Q4 2022 | -$0.17 | $7.59 M | $2.22 M | 06/02/2022 | Q3 2022 | -$0.16 | $2.01 M | 12/30/2021 | Q2 2022 | -$0.20 | $2.38 M | 09/29/2021 | Q1 2022 | -$0.17 | $2.35 M | $3.59 M | 08/31/2021 | Q4 2021 | -$0.32 | -$0.19 | 0.13 | $17.71 M | $2.00 M | 03/31/2021 | Q3 2021 | -$0.22 | $1.91 M | 12/30/2020 | Q2 2021 | -$0.22 | $2.24 M | 09/29/2020 | Q1 2021 | -$0.21 | $40.58 M | $1.29 M | 09/02/2020 | Q4 2020 | -$0.28 | $12.71 M | $692,000 | 03/31/2020 | Q3 2020 | -$0.14 | $12.08 M | 12/30/2019 | Q2 2020 | -$0.23 | $1.97 M | 09/29/2019 | Q1 2020 | -$0.06 | $2.09 M | $16.87 M | 09/09/2019 | Q4 2019 | -$0.21 | $1.62 M | $1.97 M | 03/31/2019 | Q3 2019 | -$0.25 | $1.25 M |
---|
A. Mesoblast Limited has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 28th, 2024 based off last year's report dates.
A. In the previous quarter, Mesoblast Limited (NASDAQ:MESO) reported $-0.28 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.32 by $0.04.
A. The conference call for Mesoblast Limited's latest earnings report can be listened to online.
A. The conference call transcript for Mesoblast Limited's latest earnings report can be read online.
A. Mesoblast Limited (NASDAQ:MESO) has a recorded annual revenue of $7.50 M.
A. Mesoblast Limited (NASDAQ:MESO) has a recorded net income of $7.50 M. Mesoblast Limited has generated $-1.05 earnings per share over the last four quarters.
A. Mesoblast Limited (NASDAQ:MESO) has a price-to-earnings ratio of -90.21 and price/earnings-to-growth ratio is -13.93.